在瘤学中对抗体与药物合物的QT延长风险评估中吸取的教训
Shruti D Shah1, Roxanne C Jewell2, Geraldine Ferron-Brady3
1Clinical Pharmacology Modeling and Simulation, GSK, Waltham, MA, USA. shruti.d.shah@gsk.com.
Journal of pharmacokinetics and pharmacodynamics
|July 28, 2025
概括
抗体-药物联合体 (ADC) 显示QT延长的风险较低,这是心律问题. 本次审查建议简化ADC在癌症治疗中的安全性评估.
科学领域:
- 在瘤学瘤学.
- 心血管药理学心血管药理学
- 药物开发 药物开发
背景情况:
- 抗体-药物合物 (ADC) 是一种向的癌症疗法,将抗体与细胞毒药物联系起来.
- QT延长是潜在的致命心室心律不整的危险因素,如TdP.
- 评估QT风险在瘤学中至关重要,因为患者的并发症和并发药物.
研究的目的:
- 审查FDA批准的ADCs的QT风险评估策略.
- 检查用于评估ADC心脏毒性的非临床和临床方法.
- 总结ADC中QT风险的标签策略.
主要方法:
- 审查FDA批准的ADC及其相关的QT风险评估.
- 分析非临床 (如体外,动物) 和临床 (如度-QTc) 数据.
- 检查与QT效应相关的标签信息.
主要成果:
- 一般来说,ADCs表现出较低的前节律失常风险.
- 在临床环境中观察到最小的QT间隔效应.
- 低系统有效载荷度有助于降低心脏风险.
结论:
- 为ADCs建议采用简化,适合目的的QT风险评估策略.
- 早期阶段试验中的综合评估可以优化安全评估.
- 这种方法支持癌症治疗ADC开发的持续创新.
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K


